FY2026 · ended Mar 31, 2026 · Revenue $131,000, -9.0% YoY · Filed Jul 14, 2026
VivoSim Labs, Inc. (VIVS) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In fiscal 2026, which ended Mar 31, 2026, it reported revenue of $131,000 and a net loss of $13.8 million. Free cash flow was -$10.8 million. As of Jun 30, 2026 it held $1.7 million in cash and investments and $316,000 in total debt.
Revenue
$131,000
-9.0% vs prior year
Net income
$-13.84M
-456.4% vs prior year
Operating cash flow
$-10.83M
-14.4% vs prior year
Free cash flow
$-10.83M
-14.3% vs prior year
EPS
$-5.35
-214.7% vs prior year
Dividend per share
None
Shares outstanding
3.49M
+34.4% vs prior year
Net cash
$1.35M
as of Jun 30, 2026
Operating margin
-8768.7%
FY 2026
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VIVS (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1497253
- Former names
- ORGANOVO HOLDINGS, INC. (until Apr 23, 2025); REAL ESTATE RESTORATION & RENTAL, INC. (until Oct 31, 2011)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 31, 2026 |
FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $131,000 | $144,000 | $109,000 | $370,000 | $1.5M |
| Operating income | -$11.5M | -$12.6M | -$15.1M | -$17.7M | -$11.5M |
| Net income | -$13.8M | -$2.5M | -$14.7M | -$17.3M | -$11.4M |
| Diluted EPS | -$5.35 | -$1.70 | -$19.25 | -$1.98 | — |
| Operating cash flow | -$10.8M | -$9.5M | -$14.7M | -$12.4M | -$8.5M |
| Free cash flow | -$10.8M | -$9.5M | -$14.7M | -$12.8M | -$8.9M |
| Total assets | $7.4M | $14.7M | $6.3M | $20.3M | $33.3M |
| Total liabilities | $8.5M | $4.2M | $2.7M | $5.0M | $3.1M |
| Stockholders' equity | -$1.1M | $10.5M | $3.6M | $15.3M | $30.2M |
| Cash and investments | $5.0M | $11.3M | $3.9M | $20.2M | $28.7M |
| Total debt | $447,000 | $942,000 | $1.4M | $1.8M | $2.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Oct 16, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Oct 6, 2026 | Sep 30, 2026 |
| ARS | Annual report to shareholders | Aug 21, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Listing notice
|
Aug 21, 2026 | Aug 17, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
All 819 VivoSim Labs, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.